June 2018 | Volume 2


The purchasing environment within hospital systems continues to evolve, but one thing is clear: cost and quality filter all decisions. 

Device companies are navigating shifts in the delivery of care. We asked Orthopaedic Implant Company to share the path that they chose.

About 35% of the product launches we've covered between January and mid-June came from 12 of the 20 largest orthopaedic device companies by revenue.
Prefer print?

Enter code "SOLUTIONS" at checkout and qualified OEMs pay $0; all others pay $126.

To meet your need to know who's new in the orthopaedic market, I sorted through 21 companies receiving their first orthopaedic-related FDA 510(k) clearance, then chose one company from each implantable market segment for a closer look. Here's what I found.

The study tracked 50 degenerative disease patients with an average age of 60 who underwent anterior cervical discectomy and fusion with a Cohere device, with 100% of participants experiencing positive results.

The inlay design of the implant presents an anatomic approach to treating a loss of cartilage that is limited to the central knee joint, and is an alternative to onlay implants.

Did you miss it? 

Supplier M&A activity is a significant story in orthopaedics this year. We provide tips and actionable advice in the event that one of your important suppliers is merged with or acquired by another.
From the archives:

A strategic planning process (SPP) provides a systematic way of mapping the handful of key decisions that an organization must get right in order to survive--and thrive--during the next several years. We provide six steps to implement an effective SPP at your company.